These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 28839086)

  • 1. Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
    Peloquin CA; Velásquez GE; Lecca L; Calderón RI; Coit J; Milstein M; Osso E; Jimenez J; Tintaya K; Garavito ES; Vasquez DV; Mitnick CD; Davies G
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28839086
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis.
    Peloquin CA; Velásquez GE; Lecca L; Calderón RI; Coit J; Milstein M; Osso E; Jimenez J; Tintaya K; Sanchez Garavito E; Vargas Vasquez D; Mitnick CD; Davies G
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
    Pienaar E; Dartois V; Linderman JJ; Kirschner DE
    BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum for DeMarco et al., "Determination of [
    DeMarco VP; Ordonez AA; Klunk M; Prideaux B; Wang H; Zhang Z; Tonge PJ; Dannals RF; Holt DP; Lee CKK; Weinstein EA; Dartois V; Dooley KE; Jain SK
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31444171
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.
    de Steenwinkel JE; Aarnoutse RE; de Knegt GJ; ten Kate MT; Teulen M; Verbrugh HA; Boeree MJ; van Soolingen D; Bakker-Woudenberg IA
    Am J Respir Crit Care Med; 2013 May; 187(10):1127-34. PubMed ID: 23525933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.
    Sturkenboom MG; Mulder LW; de Jager A; van Altena R; Aarnoutse RE; de Lange WC; Proost JH; Kosterink JG; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4907-13. PubMed ID: 26055359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
    Egelund EF; Isaza R; Alsultan A; Peloquin CA
    J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
    Menzies D; Dion MJ; Rabinovitch B; Mannix S; Brassard P; Schwartzman K
    Am J Respir Crit Care Med; 2004 Aug; 170(4):445-9. PubMed ID: 15172892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.
    te Brake LH; Ruslami R; Later-Nijland H; Mooren F; Teulen M; Apriani L; Koenderink JB; Russel FG; Burger DM; Alisjahbana B; Wieringa F; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2015; 59(6):3233-9. PubMed ID: 25801554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erratum for Chirehwa et al., Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction.
    Chirehwa MT; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; McIlleron H; Denti P
    Antimicrob Agents Chemother; 2016 May; 60(5):3262. PubMed ID: 27107106
    [No Abstract]   [Full Text] [Related]  

  • 12. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin.
    Gumbo T; Louie A; Deziel MR; Liu W; Parsons LM; Salfinger M; Drusano GL
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3781-8. PubMed ID: 17724157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
    van Ingen J; Aarnoutse RE; Donald PR; Diacon AH; Dawson R; Plemper van Balen G; Gillespie SH; Boeree MJ
    Clin Infect Dis; 2011 May; 52(9):e194-9. PubMed ID: 21467012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.
    Egelund EF; Isaza R; Brock AP; Alsultan A; An G; Peloquin CA
    J Vet Pharmacol Ther; 2015 Apr; 38(2):137-43. PubMed ID: 25236765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects.
    Winter H; Egizi E; Murray S; Erondu N; Ginsberg A; Rouse DJ; Severynse-Stevens D; Pauli E
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1219-24. PubMed ID: 25512422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring in the treatment of tuberculosis.
    Peloquin CA
    Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifapentine: its role in the treatment of tuberculosis.
    Temple ME; Nahata MC
    Ann Pharmacother; 1999 Nov; 33(11):1203-10. PubMed ID: 10573321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
    Park SW; Tasneen R; Converse PJ; Nuermberger EL
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
    Bergshoeff AS; Wolfs TF; Geelen SP; Burger DM
    Ann Pharmacother; 2003 Apr; 37(4):521-5. PubMed ID: 12659608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.